FDMT at a glance
4D Molecular Therapeutics, Inc. (FDMT, SEC CIK 1650648) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), 4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.2 million (up 230194.6% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$2.42.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding 4D Molecular Therapeutics, Inc. (FDMT) shares worth $285.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bizily Scott on October 16, 2026 of 1,635 shares at $12.84 per share.
- In the last 90 days, FDMT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($2.4M) on Form 4, a net sale of $2.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $85.2M
- +230194.6% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$2.4M
- 13F holders
- 27 funds
- $285.4M · +2 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $4.1M, up $4.1M YoY, driven by Otsuka clinical development cost sharing and reimbursements
- Net loss $78.1M vs $56.9M YoY, operating loss $81.2M vs $61.2M
- Worst-performing area: 4D-150 R&D expenses $43.1M, up $18.1M YoY
- Cash, equivalents and marketable securities $375.0M, operating cash used $194.8M for nine months
- Topline data expected in Q2 2027 for 4FRONT-1, with additional funding required and losses expected to continue
Risk Factors
- Newly triggered debt risk: June 2026 Hercules Loan Agreement, $20.0 million funded against $200.0 million facility
- Financial risk: $375.0 million in cash, cash equivalents and marketable securities funds planned operations for at least one year
- Regulatory risk: April 2026 proclamation imposes Section 232 tariffs on imported brand pharmaceuticals, biologics and ingredients beginning July 31, 2026
- Operational risk: September 2026 launch of 4SIGHT Phase 3 DME trial creates enrollment and execution exposure
- Competitive risk: Approved therapies from Regeneron, Roche, Vertex and others may hinder physician and payer adoption
AI summary of the FDMT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter 2026 financial results announced for the period ended September 30, 2026
- Press release includes operational highlights and expected upcoming milestones
Item EX-99.1: Item EX-99.1
- 4FRONT-1 and 4FRONT-2 randomized 523 and 531 patients, with wet AMD topline data expected Q2 2027 and H2 2027
- 4SIGHT Phase 3 initiated in DME with 514 patients, testing 4D-150 against aflibercept on vision and injection-burden reduction
Item 8.01: Other Events
- 4SIGHT Phase 3 DME trial initiated across multiple sites, enrolling 514 treatment-naïve patients globally
- Single 4SIGHT trial could support U.S. and European filings, leveraging FDA Regenerative Medicine Advanced Therapy designation
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss widened to $72.9M from $54.7M as R&D rose to $68.3M for Phase 3 wet AMD trials
- Cash, equivalents and marketable securities declined to $430.6M from $514.0M, with runway projected into H2 2028
Item 2.02: Results of Operations and Financial Condition
- Second-quarter 2026 financial results for the three months ended June 30, 2026
- Press release includes operational highlights and expected upcoming milestones
AI summaries of FDMT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FDMT
Don't miss the next FDMT filing
- Alerts as it files. A push when FDMT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FDMT, by share count.
- Ask anything. An AI agent that reads every FDMT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bizily Scott | Sell | Oct 16, 2026 | 1,635 | $12.84 |
| Bizily Scott | M | Oct 16, 2026 | 1,635 | $4.14 |
| Bizily Scott | M | Oct 16, 2026 | 1,635 | - |
| Kirn David | Sell | Oct 5, 2026 | 272 | $13.61 |
| Kirn David | Sell | Oct 5, 2026 | 58,061 | $12.92 |
| Bizily Scott | Sell | Sep 16, 2026 | 1,635 | $13.65 |
| Bizily Scott | M | Sep 16, 2026 | 1,635 | - |
| Bizily Scott | M | Sep 16, 2026 | 1,635 | $4.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $20.7M | $37K | $85.2M |
| Operating Income | - | -$187.8M | -$159.5M |
| Net Income | -$100.8M | -$160.9M | -$140.1M |
| Op. Margin | - | -507678.4% | -187.2% |
| Net Margin | -486.6% | -434778.4% | -164.4% |
| Balance Sheet | |||
| Total Assets | - | $560.4M | $566.7M |
| Equity | - | $510.6M | $505.7M |
| ROE | - | -31.5% | -27.7% |
| Per Share | |||
| EPS | $-2.58 | $-2.98 | $-2.42 |
| Cash Flow | |||
| Operating CF | - | -$134.6M | -$109.1M |
| CapEx | $2.8M | $3.8M | $536K |
Source: XBRL data in 4D Molecular Therapeutics, Inc. (FDMT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate FDMT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $285.4M |
| Q2 2026 | 25 | $266.4M |
| Q1 2026 | 26 | $170.4M |
| Q4 2025 | 24 | $140.0M |
| Q3 2025 | 24 | $150.0M |
| Q2 2025 | 24 | $67.8M |
| Q1 2025 | 21 | $48.2M |
| Q4 2024 | 17 | $41.1M |
- Morgan Stanley+587.6K (+117%)
- Bank of America Corp+414.3K (+37%)
- BlackRock+178.8K (+4%)
- Invesco Ltd+109.7K (+73%)
- Dimensional Fund Advisors+56.1K (+8%)
- Citadel Advisors LLC−533.3K (-78%)
- State Street Corp−441.7K (-15%)
- Goldman Sachs Group−328.3K (-8%)
- Renaissance Technologies LLC−202.8K (-33%)
- Wells Fargo & Co−29.5K (-71%)
- Millennium Management+136.4K
- Prudential Financial+21.5K
- StoneX Group Inc.+12.5K
- FMR LLC (Fidelity)−128.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FDMT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
Related Health Care companies
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
FDMT SEC filings: frequently asked questions
Are FDMT insiders buying or selling?
In the last 90 days, 4D Molecular Therapeutics, Inc. (FDMT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $2.4 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold FDMT stock?
As of September 30, 2026, the largest 4D Molecular Therapeutics, Inc. (FDMT) holders among the 13F filers tracked by SignalX were BlackRock ($67.6 million), Goldman Sachs Group ($56.2 million), State Street Corp ($35.3 million), Vanguard Capital Management LLC ($30.6 million), Bank of America Corp ($22.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FDMT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), 4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.2 million (up 230194.6% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$2.42. The figures come from the XBRL data in the 10-K.
What did FDMT report in its latest 8-K?
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter 2026 financial results announced for the period ended September 30, 2026.
What are the latest FDMT SEC filings?
4D Molecular Therapeutics, Inc. (FDMT) filed its latest 10-K annual report on March 18, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 20, 2026.
What is FDMT's SEC CIK number?
4D Molecular Therapeutics, Inc. (FDMT)'s SEC Central Index Key (CIK) is 1650648. EDGAR lists every FDMT filing under that number.
Ask anything about FDMT
The research agent reads FDMT's filings, financials, insider trades and 13F holders, then answers with sources.